Interactions of tachykinin receptor antagonists with lipopolysaccharide-induced airway inflammation in mice

Authors: M Veron1; I Guenon1; S Nenan1; X Emonds-Alt2; C Advenier3; V Lagente1; E Boichot1

Source: Clinical and Experimental Pharmacology and Physiology, Volume 31, Number 9, September 2004 , pp. 634-640(7)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Summary

1. Several observations suggest that tachykinins are involved in the pathogenesis of bronchopulmonary alterations. We have investigated the effect of antagonists for tachykinin NK1 (SR 140333), NK2 (SR 48968) or NK3 (SR 142801) receptors on inflammatory cell recruitment, tumour necrosis factor (TNF)-agr and interleukin (IL)-6 release and matrix metalloproteinase (MMP)-9 activity in the bronchoalveolar lavage fluid (BALF) of mice exposed to lipopolysaccharide (LPS; 100 µg/mL aerosol for 30 min).

2. Treatment of mice with a combination of SR 140333 and SR 48968 (10-6 mol/L, aerosol) significantly reduced the increase in the number of total cells and neutrophils and MMP-9 activity in the BALF of mice 2.5 h after LPS exposure. Treatment with the NK3 antagonist SR 142801 (10-6 mol/L, aerosol) did not inhibit the influx of neutrophils, but markedly reduced the increase in TNF-agr and IL-6 levels at 2.5 h and MMP-9 activity at 20 h.

3. These results show that the three tachykinin receptor antagonists may interfere with the development of airway inflammation, namely neutrophilia, TNF-agr release or MMP-9 activity in the BALF of mice exposed to LPS and suggest that not only NK1 and NK2 receptors, but also NK3 receptors are involved in the modulation of the inflammatory response and airway remodelling.

Keywords: airway inflammation; lipopolysaccharide; metalloproteinase; mice; SR 142801; tachykinin

Document Type: Research article

DOI: 10.1111/j.1440-1681.2004.04061.x

Affiliations: 1: Faculté de Pharmacie, Université de Rennes 1, Rennes, 2: Sanofi-Synthélabo recherche Montpellier and 3: UPRES-EA220-Pharmacologie, UFR Biomédicale des Saints-Pères, Université Paris V, Paris, France

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A